Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;28(10):3384-3395.
doi: 10.1111/ene.14690. Epub 2021 Jan 9.

COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Ana Zabalza  1 , Simón Cárdenas-Robledo  1 , Paula Tagliani  1 , Georgina Arrambide  1 , Susana Otero-Romero  1 , Pere Carbonell-Mirabent  1 , Marta Rodriguez-Barranco  1 , Breogán Rodríguez-Acevedo  1 , Juan Luis Restrepo Vera  1 , Mireia Resina-Salles  1 , Luciana Midaglia  1 , Angela Vidal-Jordana  1 , Jordi Río  1 , Ingrid Galan  1 , Joaquin Castillo  1 , Álvaro Cobo-Calvo  1 , Manuel Comabella  1 , Carlos Nos  1 , Jaume Sastre-Garriga  1 , Mar Tintore  1 , Xavier Montalban  1
Affiliations

COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Ana Zabalza et al. Eur J Neurol. 2021 Oct.

Abstract

Background and purpose: Information regarding multiple sclerosis (MS) patients with the 2019 novel coronavirus disease (COVID-19) is scarce. The study objective was to describe the incidence and characteristics of MS patients with COVID-19, to identify susceptibility and severity risk factors and to assess the proportion of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologies according to disease-modifying treatments.

Methods: This was a retrospective study of an MS cohort analysing data collected between February and May 2020. Cases were identified through an email survey and clinical visits. The relationship of demographic and MS characteristics with COVID-19 and of the disease-modifying treatments with SARS-CoV-2 serostatus were examined.

Results: Data from 48 suspected cases out of 758 valid respondents and from 45 COVID-19 cases identified through clinical visits were collected. Incidence was 6.3%. Nineteen (20.3%) patients were hospitalized and two (2.2%) died. Multivariable models determined that age (odds ratio [OR] per 10 years 0.53, 95% confidence interval [CI] 0.34-0.85), contact with a confirmed case (OR 197.02, 95% CI 56.36-688.79), residence in Barcelona (OR 2.23, 95% CI 1.03-4.80), MS duration (OR per 5 years 1.41, 95% CI 1.09-1.83) and time on anti-CD20 treatment (OR per 2 years 3.48, 95% CI 1.44-8.45) were independent factors for presenting COVID-19 and age (OR per 10 years 2.71, 95% CI 1.13-6.53) for a severe COVID-19. Out of the 79 (84.9%) with serological test, 45.6% generated antibodies, but only 17.6% of those on anti-CD20 therapies. Lymphopaenia or immunoglobulin levels did not relate to COVID-19.

Conclusions: Multiple sclerosis patients present similar incidence, risk factors and outcomes for COVID-19 as the general population. Patients treated with an anti-CD20 therapy for a longer period of time might be at a higher risk of COVID-19 and less than 20% generate an antibody response. Only age was related to severity.

Keywords: COVID-19; SARS-CoV-2; disease-modifying therapy; multiple sclerosis; risk factors.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Zhou P, Lou YX, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7
    1. Sastre-Garriga J, Tintoré M, Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Mult Scler J. 2020;26(10):1153-1156. https://doi.org/10.1177/1352458520931785
    1. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Dades actualitzades SARS-CoV-2. https://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus/. Published 2020. Accessed October 14, 2020.
    1. Persson R, Lee S, Ulcickas Yood M, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41:101982. https://doi.org/10.1016/j.msard.2020.101982
    1. Celius EG. Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand. 2017;136:34-36. https://doi.org/10.1111/ane.12835

LinkOut - more resources